vs
Side-by-side financial comparison of LANDMARK BANCORP INC (LARK) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ARS Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($28.1M vs $18.8M, roughly 1.5× LANDMARK BANCORP INC). LANDMARK BANCORP INC runs the higher net margin — 27.0% vs -147.1%, a 174.1% gap on every dollar of revenue. On growth, LANDMARK BANCORP INC posted the faster year-over-year revenue change (14.0% vs -67.6%).
Landmark Bancorp Inc is a U.S.-based bank holding company operating Landmark National Bank, primarily serving communities across Kansas. It provides a full range of personal and commercial banking services including deposit accounts, residential mortgages, commercial loans, and wealth management solutions, catering to individual consumers, small businesses and local mid-sized enterprises.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
LARK vs SPRY — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.8M | $28.1M |
| Net Profit | $5.1M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | — | -147.6% |
| Net Margin | 27.0% | -147.1% |
| Revenue YoY | 14.0% | -67.6% |
| Net Profit YoY | 7.8% | -182.8% |
| EPS (diluted) | — | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $18.8M | — | ||
| Q4 25 | $18.7M | $28.1M | ||
| Q3 25 | $18.2M | $32.5M | ||
| Q2 25 | $17.3M | $15.7M | ||
| Q1 25 | $16.5M | $8.0M | ||
| Q4 24 | $15.8M | $86.6M | ||
| Q3 24 | $15.9M | $2.1M | ||
| Q2 24 | $14.7M | $500.0K |
| Q1 26 | $5.1M | — | ||
| Q4 25 | $4.7M | $-41.3M | ||
| Q3 25 | $4.9M | $-51.2M | ||
| Q2 25 | $4.4M | $-44.9M | ||
| Q1 25 | $4.7M | $-33.9M | ||
| Q4 24 | $3.3M | $49.9M | ||
| Q3 24 | $3.9M | $-19.1M | ||
| Q2 24 | $3.0M | $-12.5M |
| Q1 26 | — | — | ||
| Q4 25 | 31.7% | -147.6% | ||
| Q3 25 | 33.4% | -163.7% | ||
| Q2 25 | 30.9% | -302.9% | ||
| Q1 25 | 34.7% | -466.3% | ||
| Q4 24 | 15.2% | 54.5% | ||
| Q3 24 | 30.3% | -1051.6% | ||
| Q2 24 | 24.5% | -3068.0% |
| Q1 26 | 27.0% | — | ||
| Q4 25 | 32.1% | -147.1% | ||
| Q3 25 | 27.1% | -157.4% | ||
| Q2 25 | 25.4% | -285.6% | ||
| Q1 25 | 28.5% | -425.7% | ||
| Q4 24 | 26.5% | 57.7% | ||
| Q3 24 | 24.8% | -925.0% | ||
| Q2 24 | 20.5% | -2503.2% |
| Q1 26 | — | — | ||
| Q4 25 | $0.66 | $-0.41 | ||
| Q3 25 | $0.85 | $-0.52 | ||
| Q2 25 | $0.75 | $-0.46 | ||
| Q1 25 | $0.81 | $-0.35 | ||
| Q4 24 | $0.47 | $0.52 | ||
| Q3 24 | $0.68 | $-0.20 | ||
| Q2 24 | $0.52 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.9M | $245.0M |
| Total DebtLower is stronger | — | $96.4M |
| Stockholders' EquityBook value | — | $114.3M |
| Total Assets | $1.6B | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $31.9M | — | ||
| Q4 25 | — | $245.0M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | — | $240.1M | ||
| Q1 25 | — | $275.7M | ||
| Q4 24 | — | $314.0M | ||
| Q3 24 | — | $204.6M | ||
| Q2 24 | — | $218.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $160.6M | $114.3M | ||
| Q3 25 | $155.7M | $147.7M | ||
| Q2 25 | $148.4M | $192.3M | ||
| Q1 25 | $142.7M | $229.0M | ||
| Q4 24 | $136.2M | $256.8M | ||
| Q3 24 | $139.7M | $201.0M | ||
| Q2 24 | $128.3M | $215.2M |
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $327.7M | ||
| Q3 25 | $1.6B | $372.8M | ||
| Q2 25 | $1.6B | $313.5M | ||
| Q1 25 | $1.6B | $327.3M | ||
| Q4 24 | $1.6B | $351.2M | ||
| Q3 24 | $1.6B | $217.6M | ||
| Q2 24 | $1.6B | $222.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-43.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $21.6M | $-43.5M | ||
| Q3 25 | $10.3M | $-47.0M | ||
| Q2 25 | $439.0K | $-39.6M | ||
| Q1 25 | $8.0M | $-40.7M | ||
| Q4 24 | $14.2M | $42.0M | ||
| Q3 24 | $8.1M | $-14.5M | ||
| Q2 24 | $4.4M | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | $21.0M | — | ||
| Q3 25 | $10.1M | $-47.2M | ||
| Q2 25 | $354.0K | $-39.6M | ||
| Q1 25 | $8.0M | $-40.8M | ||
| Q4 24 | $11.9M | $41.7M | ||
| Q3 24 | $7.8M | $-14.6M | ||
| Q2 24 | $3.8M | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | 112.5% | — | ||
| Q3 25 | 55.4% | -145.4% | ||
| Q2 25 | 2.0% | -252.2% | ||
| Q1 25 | 48.4% | -512.1% | ||
| Q4 24 | 75.6% | 48.2% | ||
| Q3 24 | 49.3% | -706.3% | ||
| Q2 24 | 25.6% | -1463.4% |
| Q1 26 | — | — | ||
| Q4 25 | 3.2% | 0.0% | ||
| Q3 25 | 1.4% | 0.6% | ||
| Q2 25 | 0.5% | 0.3% | ||
| Q1 25 | 0.3% | 1.1% | ||
| Q4 24 | 14.7% | 0.3% | ||
| Q3 24 | 1.8% | 6.8% | ||
| Q2 24 | 4.2% | 7.6% |
| Q1 26 | — | — | ||
| Q4 25 | 4.56× | — | ||
| Q3 25 | 2.09× | — | ||
| Q2 25 | 0.10× | — | ||
| Q1 25 | 1.71× | — | ||
| Q4 24 | 4.34× | 0.84× | ||
| Q3 24 | 2.06× | — | ||
| Q2 24 | 1.45× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LARK
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
